Monoclonal antibodies to cachectin/tumor necrosis factor and methods for preparing same
AssigneeThe Rockefeller University
InventorsStephen D. Wolpe, Anthony Cerami
Life of this patent
Estimating the term…
Abstract
The present invention pertains to the novel hybridoma SDW18.1.1, hybridomas obtained from SDW18.1.1, monoclonal antibodies obtained from such hybridomas and derivatives of such monoclonal antibodies. The novel hybridomas are formed by fusion of cells from a mouse myeloma line and spleen cells from a mouse previously immunized with cachectin/TNF. Diagnostic and therapeutic utilities for the monoclonal antibodies and their derivatives are proposed, and testing procedures, materials in kit form and pharmaceutical compositions are likewise set forth.
Claims14
A monoclonal antibody produced by a hybridoran cell line having the identifying characteristics of A.T.C.C. Accession No. HB 9228, which hybridoma is formed by fusion of cells from a mouse myeloma line and spleen cells from a mouse previously immunized with cachectin/TNF, which antibody reacts with cachectin/TNF.
The monoclonal antibody produced by the hybridoma cell line having the identifying characteristic of A.T.C.C. Accession No. HB 9228.
A method of preparing monoclonal antibody which reacts with cachectin/TNF which comprises culturing the hybridoma cell line having the identifying characteristic of A.T.C.C. Accession No. HB 9228 in a suitable medium and recovering the antibody from the culture supernatant.
A method of preparing monoclonal antibody which reacts with cachectin/TNF which comprises injecting into a mouse the hybridoma cell line having the identifying characteristic of A.T.C.C. Accession No. HB 9228 and recovering the antibody from the malignant ascites or serum of the mouse.
A hybridoran cell line having the identifying characteristics of A.T.C.C Accession No. HB 9228, which hybridoran produces monoclonal antibodies that react with cachectin/TNF.
A pharmaceutical composition for the treatment of shock, and/or cachexia in mammals, comprising:
- A. a pharmaceutically effective amount of material selected from the group consisting of an antibody to cachectin TNF produced by a hybridoran cell line having the identifying characteristics of A.T.C.C. Accession No. HB 9228, an antibody to said antibody to cachectin/TNF, and mixture thereof, or a specified binding partner thereto;
- and
- B. a pharmaceutically effective carrier.
Dependencies are inferred from the claim text.